The University of Chicago Header Logo

Connection

Richard Schilsky to Antineoplastic Combined Chemotherapy Protocols

Back to Details
This is a "connection" page, showing publications Richard Schilsky has written about Antineoplastic Combined Chemotherapy Protocols.
Richard Schilsky
Connection Strength
4.405
Antineoplastic Combined Chemotherapy Protocols
  1. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 04; 7:e2200609.
    View in: PubMed
    Score: 0.439
  2. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 10; 6:e2200306.
    View in: PubMed
    Score: 0.425
  3. Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011 Nov-Dec; 61(6):365-81.
    View in: PubMed
    Score: 0.199
  4. First-line treatment options for patients with metastatic colorectal cancer. Nat Clin Pract Oncol. 2004 Dec; 1(2):70-1.
    View in: PubMed
    Score: 0.123
  5. Cetuximab in the treatment of colorectal cancer. Clin Adv Hematol Oncol. 2004 Nov; 2(11):1-10; quiz 11-12.
    View in: PubMed
    Score: 0.123
  6. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004 Mar 22; 90(6):1190-7.
    View in: PubMed
    Score: 0.118
  7. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep; 7:e2300279.
    View in: PubMed
    Score: 0.113
  8. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 07; 11(14):2790-2800.
    View in: PubMed
    Score: 0.102
  9. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol. 2002 Mar 15; 20(6):1519-26.
    View in: PubMed
    Score: 0.102
  10. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
    View in: PubMed
    Score: 0.101
  11. Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer. 2001 Aug; 1(2):95-103.
    View in: PubMed
    Score: 0.098
  12. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med. 2001 Jul 12; 345(2):144-5; author reply 146.
    View in: PubMed
    Score: 0.098
  13. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31.
    View in: PubMed
    Score: 0.091
  14. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
    View in: PubMed
    Score: 0.084
  15. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7.
    View in: PubMed
    Score: 0.078
  16. A New IDEA in Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2018 03 29; 378(13):1242-1244.
    View in: PubMed
    Score: 0.078
  17. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
    View in: PubMed
    Score: 0.074
  18. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res. 1997 May; 3(5):719-25.
    View in: PubMed
    Score: 0.073
  19. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996 Nov; 14(11):3000-8.
    View in: PubMed
    Score: 0.070
  20. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. J Clin Oncol. 2016 11 10; 34(32):3872-3879.
    View in: PubMed
    Score: 0.070
  21. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol. 1996 Jun; 14(6):1964-5.
    View in: PubMed
    Score: 0.068
  22. Adjuvant therapy of colon cancer. Semin Oncol. 1995 Dec; 22(6):600-10.
    View in: PubMed
    Score: 0.066
  23. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol. 1995 Sep; 13(9):2230-7.
    View in: PubMed
    Score: 0.065
  24. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Jun 10; 6(16):14139-52.
    View in: PubMed
    Score: 0.064
  25. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015 Feb 18; 15:69.
    View in: PubMed
    Score: 0.063
  26. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol. 1994 Dec; 12(12):2743-50.
    View in: PubMed
    Score: 0.062
  27. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336.
    View in: PubMed
    Score: 0.062
  28. Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother Pharmacol. 1994; 34(6):509-14.
    View in: PubMed
    Score: 0.058
  29. American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013 Dec 01; 31(34):4362-70.
    View in: PubMed
    Score: 0.057
  30. Update on biochemical modulation of chemotherapeutic agents. Oncology (Williston Park). 1993 May; 7(5):99-106, 109; discussion 110-4, 117.
    View in: PubMed
    Score: 0.055
  31. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. Cancer Res. 1993 Mar 15; 53(6):1293-6.
    View in: PubMed
    Score: 0.055
  32. Laboratory and clinical studies of biochemical modulation by hydroxyurea. Semin Oncol. 1992 Jun; 19(3 Suppl 9):84-9.
    View in: PubMed
    Score: 0.052
  33. A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. Eur J Cancer. 1991; 27(2):217-8.
    View in: PubMed
    Score: 0.047
  34. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22.
    View in: PubMed
    Score: 0.045
  35. Nonmalignant complications of therapy for Hodgkin's disease. Hematol Oncol Clin North Am. 1989 Jun; 3(2):331-43.
    View in: PubMed
    Score: 0.042
  36. Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing. Cancer. 1989 Mar 15; 63(6 Suppl):1018-21.
    View in: PubMed
    Score: 0.041
  37. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 01; 26(31):5043-51.
    View in: PubMed
    Score: 0.040
  38. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar; 46(3):303-8.
    View in: PubMed
    Score: 0.039
  39. Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma. J Clin Oncol. 1987 Mar; 5(3):419-25.
    View in: PubMed
    Score: 0.036
  40. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer. Cancer Res. 1986 Aug; 46(8):4184-8.
    View in: PubMed
    Score: 0.035
  41. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20; 97(14):1080-3.
    View in: PubMed
    Score: 0.032
  42. Cytarabine-cis-platin interactions in patients with advanced cancer. Semin Oncol. 1985 Jun; 12(2 Suppl 3):171-6.
    View in: PubMed
    Score: 0.032
  43. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 01; 23(10):2191-200.
    View in: PubMed
    Score: 0.031
  44. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.
    View in: PubMed
    Score: 0.031
  45. Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer. Cancer Treat Rep. 1984 Sep; 68(9):1097-102.
    View in: PubMed
    Score: 0.030
  46. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83.
    View in: PubMed
    Score: 0.027
  47. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9.
    View in: PubMed
    Score: 0.027
  48. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
    View in: PubMed
    Score: 0.027
  49. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol. 2002 Jan; 13(1):87-91.
    View in: PubMed
    Score: 0.025
  50. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Leuk Lymphoma. 2001 Nov-Dec; 42(6):1255-64.
    View in: PubMed
    Score: 0.025
  51. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr 01; 91(7):1256-63.
    View in: PubMed
    Score: 0.024
  52. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2000 Aug; 18(15):2894-901.
    View in: PubMed
    Score: 0.023
  53. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999 Sep; 5(9):2289-96.
    View in: PubMed
    Score: 0.021
  54. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758.
    View in: PubMed
    Score: 0.021
  55. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs. 1999; 17(1):97-101.
    View in: PubMed
    Score: 0.020
  56. Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108.
    View in: PubMed
    Score: 0.020
  57. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. J Clin Oncol. 1998 Oct; 16(10):3302-9.
    View in: PubMed
    Score: 0.020
  58. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol. 1998 Sep; 9(9):1035-7.
    View in: PubMed
    Score: 0.020
  59. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998 Jan; 16(1):19-26.
    View in: PubMed
    Score: 0.019
  60. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32.
    View in: PubMed
    Score: 0.018
  61. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol. 1996 Oct; 14(10):2674-81.
    View in: PubMed
    Score: 0.018
  62. Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59.
    View in: PubMed
    Score: 0.017
  63. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
    View in: PubMed
    Score: 0.016
  64. 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. Ann Oncol. 1993 Aug; 4(7):591-5.
    View in: PubMed
    Score: 0.014
  65. Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B. Cancer. 1991 Oct 15; 68(8):1696-8.
    View in: PubMed
    Score: 0.012
  66. Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. Med Pediatr Oncol. 1991; 19(1):8-15.
    View in: PubMed
    Score: 0.012
  67. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb; 8(2):241-7.
    View in: PubMed
    Score: 0.011
  68. Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B. Med Pediatr Oncol. 1990; 18(3):197-202.
    View in: PubMed
    Score: 0.011
  69. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8.
    View in: PubMed
    Score: 0.011
  70. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989 Mar 15; 63(6 Suppl):1048-53.
    View in: PubMed
    Score: 0.010
  71. A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer. 1989 Jan 01; 63(1):30-6.
    View in: PubMed
    Score: 0.010
  72. Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6.
    View in: PubMed
    Score: 0.010
  73. Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg. 1988 Apr; 98(4):295-8.
    View in: PubMed
    Score: 0.010
  74. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol. 1988 Apr; 6(4):618-26.
    View in: PubMed
    Score: 0.010
  75. Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6.
    View in: PubMed
    Score: 0.010
  76. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2584-6.
    View in: PubMed
    Score: 0.007
  77. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. Clin Colorectal Cancer. 2002 Nov; 2(3):140-5.
    View in: PubMed
    Score: 0.007
  78. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.